Merck & Co. Target of Unusually Large Options Trading (MRK)
Shares of Merck & Co. (NYSE:MRK) saw unusually large options trading activity on Monday. Stock investors purchased 5,003 put options on the stock, Analyst Ratings.Net reports. This represents an increase of approximately 111% compared to the average daily volume of 2,366 put options.
In other Merck & Co. news, EVP Adam H. Schechter unloaded 22,000 shares of Merck & Co. stock in a transaction dated Monday, August 25th. The stock was sold at an average price of $59.70, for a total value of $1,313,400.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.
A number of research firms have recently commented on MRK. Analysts at Zacks reiterated a “neutral” rating on shares of Merck & Co. in a research note on Monday, August 18th. They now have a $62.00 price target on the stock. Separately, analysts at Jefferies Group cut their price target on shares of Merck & Co. from $63.00 to $60.00 in a research note on Monday, August 11th. They now have a “hold” rating on the stock. Finally, analysts at Credit Suisse reiterated a “neutral” rating on shares of Merck & Co. in a research note on Thursday, July 31st. They now have a $59.00 price target on the stock, up previously from $56.00. Seven investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. The company currently has a consensus rating of “Buy” and a consensus target price of $60.64.
Merck & Co. (NYSE:MRK) traded up 0.95% on Monday, hitting $59.73. The stock had a trading volume of 5,170,831 shares. Merck & Co. has a 52-week low of $44.62 and a 52-week high of $59.84. The stock has a 50-day moving average of $57.89 and a 200-day moving average of $57.00. The company has a market cap of $172.3 billion and a price-to-earnings ratio of 31.17.
Merck & Co. (NYSE:MRK) last issued its quarterly earnings data on Tuesday, July 29th. The company reported $0.85 EPS for the quarter, beating the Thomson Reuters consensus estimate of $0.80 by $0.05. The company had revenue of $10.93 billion for the quarter, compared to the consensus estimate of $10.60 billion. During the same quarter last year, the company posted $0.84 earnings per share. Merck & Co.’s revenue was down .7% compared to the same quarter last year. On average, analysts predict that Merck & Co. will post $3.49 earnings per share for the current fiscal year.
The company also recently announced a quarterly dividend, which is scheduled for Tuesday, October 7th. Investors of record on Monday, September 15th will be paid a dividend of $0.44 per share. This represents a $1.76 annualized dividend and a dividend yield of 2.95%. The ex-dividend date is Thursday, September 11th.
Merck & Co, Inc (NYSE:MRK), is a global health care company that delivers health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products, which it markets directly and through its joint ventures.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.